ICER Publishes Cost-Effectiveness Study of Remdesivir for COVID-19 Patients

Researchers from the Institute for Clinical and Economic Review have published their cost-effectiveness analysis of remdesivir in the most recent issue of ISPOR’s Value in Health. Although the drug has definite benefits for hospitalized patients, ICER’s analysis shows that the current price is too high for the benefits it provides, especially if survival improvements are not assumed. A key factor involved in the analysis is how hospitals are reimbursed for COVID-19 care.

According to the paper, “Under an assumption that hospitalizations are paid as a bundled payment dependent on the level of respiratory support required, as in our base-case analysis, the cost-effectiveness of remdesivir becomes more favorable when more costly hospitalization bundled payments are prevented (eg, preventing the progression to a hospitalization that includes mechanical ventilation). Under a per diem hospitalization reimbursement structure, the value profile for remdesivir improves if there is a length of stay improvement associated with the treatment.”

Read the study by clicking here.

(Source: Value in Health, February 19^th, 2022)